Efficacy and safety of nintedanib 1 docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO

被引：0
|
作者：
Grohe, C. [1 ]
Gleiber, W. [2 ]
Haas, S. [3 ,4 ]
Krueger, S. [5 ]
Schulze, M. [6 ]
Atz, J. [7 ]
Kaiser, R. [7 ]
机构：
[1] ELK Berlin, Dept Pneumol, Berlin, Germany
[2] Univ Hosp Frankfurt, Pneumol Allergol, Frankfurt, Germany
[3] FEK, Clin Haematol, Neumunster, Germany
[4] FEK, Clin Oncol & Nephrol, Neumunster, Germany
[5] Florence Nightingale Hosp, Dept Pulmonol Allergol Sleep Med & Resp Care, Dusseldorf, Germany
[6] Ambulante Onkol Ostsachsen, Zittau, Germany
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Med Affairs Oncol, Ingelheim, Germany
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1505P
引用
收藏
页码：618 / 618
页数：1
相关论文
共 50 条
  • [31] Etanercept in Monotherapy and in Combination with Methotrexate: Results of an Evaluation from the prospective non-interventional Study (NIS) to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Psoriatic Arthritis
    Lorenz, H.
    Jobst, J.
    Loeschmann, P.
    Prinz, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 125 - 126
  • [32] Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study
    Hu, Fang
    Peng, Jin
    Niu, Yanjie
    Mao, Xiaowei
    Zhao, Yizhuo
    Jiang, Liyan
    JOURNAL OF THORACIC DISEASE, 2022, 14 (10)
  • [33] Efficacy and safety of anlotinib plus docetaxel in non-small cell lung cancer (NSCLC) after failure of previous immune checkpoint inhibitors (ICIs) therapy: Results from a phase I/II trial
    Fang, Y.
    Pan, H.
    Shou, J.
    Hong, W.
    Chen, J.
    Wang, Y.
    Guo, Q.
    Lu, L.
    Rao, C.
    Yang, X.
    Zhu, D.
    Lan, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1021 - S1021
  • [34] EFFICACY AND SAFETY OF SALVAGE CHEMOTHERAPY FOLLOWING EXPOSURE TO IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Makio, Takechi
    Hara, S.
    Hosoi, K.
    Kinishita, Y.
    Min, K.
    RESPIROLOGY, 2017, 22 : 114 - 115
  • [35] Anlotinib plus docetaxel in the treatment of non-small cell lung cancer (NSCLC) after failure of previous immune checkpoint inhibitors (ICIs) therapy: Updated results from a pooled analysis of two phase II trials
    Pan, H.
    Fang, Y.
    Wu, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1026 - S1026
  • [36] A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world
    Shi, Yue
    Ji, Min
    Jiang, Yingying
    Yin, Rong
    Wang, Zihan
    Li, Hang
    Wang, Shuaiyu
    He, Kang
    Ma, Yuxin
    Wang, Zhitong
    Lu, Jianwei
    Shi, Meiqi
    Shen, Bo
    Zhou, Guoren
    Leong, Tracy L.
    Wang, Xiaohua
    Chen, Cheng
    Feng, Jifeng
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (06) : 1051 - 1068
  • [37] Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study
    Zhang, Dongming
    Shi, Yuequan
    Liu, Xiaoyan
    Liu, Jia
    Xu, Yan
    Zhao, Jing
    Zhong, Wei
    Hakozaki, Taiki
    Provencio, Mariano
    Horita, Nobuyuki
    Fukuda, Nobuhiko
    Chen, Minjiang
    Wang, Mengzhao
    Kasmann, Lukas
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (07) : 1420 - 1433
  • [38] Safety and efficacy of the thrombopoietin receptor agonist Eltrombopag in patients with chronic Immune Thrombocytopenia (cITP) in routine healthcare - results of the 1st interim analysis of the non-interventional study RISA
    Meyer, O.
    Reiser, M.
    Doerfel, S.
    Schlag, R.
    Kaempfe, D.
    Welslau, M.
    Losem, C.
    Zahn, M. -O.
    von der Heyde, E.
    Ehrnsperger, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 195 - 196
  • [39] Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study
    Barlesi, F.
    Greillier, L.
    Monville, F.
    Foa, C.
    le Treut, J.
    Audigier-Valette, C.
    Vely, F.
    Garcia, S.
    Sabatier, F.
    Ciccolini, J.
    Fabre, M.
    Le Ray, M.
    Resseguier, N.
    Outters, P.
    Roumieux, M.
    Mazieres, J.
    Perol, M.
    Vivier, E.
    Auquier, P.
    Fieschi, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1183 - S1183
  • [40] Efficacy and safety of combining radiotherapy with immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a real-world study
    Yang, Guanli
    Zhou, Zhen
    Liu, Chengxin
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2024, 46 (06) : 861 - 871
12345